Clinical beta
FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.
Drug Monograph
USE IF: Hyperkalemia with ECG changes, hypocalcemia, selected toxicology (e.g., calcium channel blocker overdose)
AVOID IF: Hypercalcemia; use caution in digoxin toxicity (context-dependent)
Calcium Gluconate
IV calcium salt for emergent membrane stabilization and calcium replacement
Indication
Hyperkalemia (cardiac stabilization) • Hypocalcemia • Toxicology (selected)
INDICATIONS (CORE USE)
- Hyperkalemia with ECG changes - Hypocalcemia - Calcium channel blocker toxicity (selected)
ADULT DOSE (STANDARD)
IV bolus dosing per protocol May repeat if ECG changes persist
MAX DOSE
Protocol- and ECG-response guided; avoid unnecessary repeat boluses without reassessment
Route
IV
PEDIATRIC DOSE
Protocol-based
Must-not-miss safety points
Major warning
- Does NOT lower potassium - Stabilizes myocardium only - Give early in hyperkalemia with ECG changes - Effect is temporary and repeat dosing may be required
Institutional protocol required
Dosing for this medication is not a substitute for your hospital order set, pharmacy verification, or specialty protocol. Use only with an approved institutional pathway, continuous monitoring, and independent double-check where policy requires.
FMBM beta: decision support only — not medical advice or a prescribing system.
INDICATION: Hyperkalemia (cardiac stabilization) • Hypocalcemia • Toxicology (selected)
Primary
Secondary
Institutional protocol required
Dosing for this medication is not a substitute for your hospital order set, pharmacy verification, or specialty protocol. Use only with an approved institutional pathway, continuous monitoring, and independent double-check where policy requires.
Numeric examples in this monograph are illustrative only when present — always follow your verified institutional protocol and product labeling.
FMBM beta: decision support only — not medical advice or a prescribing system.
STANDARD (ADULT PO)
IV bolus dosing with repeat guided by ECG response
ADULT DOSE
STANDARD (ADULT): - IV bolus dosing - Repeat based on ECG response
PEDIATRIC DOSE
Protocol-based
MAX DOSE
No fixed universal maximum in emergencies; reassess need using ECG and clinical response
Practical Note
- Give before potassium-shifting therapies if ECG changes are present - Monitor ECG response continuously during acute care
Clinical warnings
Adverse effects
Pediatrics
Protocol-based
Pregnancy
Cardiac disease: Use with monitoring and ECG oversight Pregnancy/
Lactation
Use per emergency indication and protocol guidance.
Renal impairment
Monitor calcium balance closely, especially with repeated dosing.
Hepatic impairment
No primary hepatic dose adjustment for emergent use; monitor overall critical-care response.
Elderly
Use with monitoring due to higher vulnerability to hemodynamic and rhythm disturbances.
- IV slow administration - Avoid extravasation - Continuous cardiac monitoring in acute use
Clinical Picture
Hypercalcemia and arrhythmias
Immediate Actions
Stop administration and provide supportive care
Antidote
None specific
Decontamination
Supportive toxicology-directed management
Escalation
Escalate for persistent arrhythmia, severe hypercalcemia, or hemodynamic instability
Common mistakes, resistance logic, and bedside traps
- Rapid onset - Short duration
- Stabilizes cardiac membrane by restoring threshold potential
Saudi Arabia
Calcium gluconate (IV)
Global
Calcium gluconate, (placeholder — verify local formulation)
Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.
Global data (no country-specific data available)
Saudi Arabia
International